Increasing Her2/Centromere17(CEP17) ratio predicts for greater sensitivity to trastuzumab based therapy in metastatic breast cancer (MBC)
S. Howell, A. Sawyerr, A. Cramer, D. Ryder, A.M. WardleyVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70795-x
File:
PDF, 56 KB
english, 2008